Dr.Payal Mukherji

Dr.NEHA SHILPY, Dr. Suchitra Kumari, dr. SINHA VIDYA BHUSHAN

Abstract

Objective- to study effects of topical dorzolamide-timolol vs placebo in wet ARMD patients with persistent exudation after intravitreal anti-VEGF injections.

Materials and Methods- Patients of wet ARMD with monthly bevacizumab injections, aged between 50-75 years, were evaluated between July2018 to June2019. Detailed eye examination (VA, fundoscopy, OCT, FFA) was done. They were randomly divided into 2 groups- 1st group were given topical dorzolamide-timolol, 2nd group were given lubricants daily for 12 weeks. All patients were followed up monthly for 3 months.

Result- Total 49 eyes with wet ARMD taking bevacizumab were identified. VA was stable over 3months but significant decrease in central subfield thickness, subretinal fluid height and PED height of patients were observed after topical dorzolamide-timolol instillation, as compared to placebo.

Conclusion- Dorzolamide-timolol resulted in anatomic improvements in patients of wet ARMD taking monthly bevacizumab over 3months.